Stefanie Dietz-Ziegler, Samantha Kewitz, Gabriele Kaiser, Jessica Rühle, Alexander Marmé, Alexander Dalpke, Bachar Cheaib, Jan Pauluschke-Fröhlich, Melanie Henes, Ana Velic, Andreas Pich, Anneli Vollert, Martin Schaller, Felix Knab, Trim Lajqi, Christian F. Poets, Christian Gille, Natascha Köstlin-Gille
Pregnancy requires immune tolerance to a semi-allogeneic fetus, involving profound adaptations, particularly in the T helper (Th) cell response. The intestinal microbiome plays a crucial role in health, but its influence on immune adaptation to pregnancy remains unclear. Bacterial extracellular vesicles (BEVs), released by gut bacteria, can cross the intestinal barrier and modulate immune responses. In our study we investigated the effect of fecal EVs (fEVs) from pregnant women on Th cell composition in vitro. fEVs were purified from preserved stool samples, characterized, and their uptake by immune cells was analyzed. Using an in vitro T cell culture model, we examined Th cell phenotypes, intracellular cytokine expression, and proteomic changes after stimulation with fEVs from pregnant and non-pregnant women. We demonstrate that fEVs from preserved stool samples are rapidly taken up by T cells and modulate their phenotype. Stimulation with fEVs from pregnant women shifts Th cells toward a regulatory profile favorable for pregnancy, increasing Th2 cells while reducing Th17 cells compared to fEVs from non-pregnant controls. This study provides the first in vitro evidence that fecal-derived EVs influence immune adaptation to pregnancy and may offer a basis for microbiome-targeted strategies to prevent or treat immunological pregnancy complications.
{"title":"Extracellular Vesicles Derived From the Feces of Pregnant Women Modulate T Cells Toward a Pregnancy-Supportive Phenotype In Vitro","authors":"Stefanie Dietz-Ziegler, Samantha Kewitz, Gabriele Kaiser, Jessica Rühle, Alexander Marmé, Alexander Dalpke, Bachar Cheaib, Jan Pauluschke-Fröhlich, Melanie Henes, Ana Velic, Andreas Pich, Anneli Vollert, Martin Schaller, Felix Knab, Trim Lajqi, Christian F. Poets, Christian Gille, Natascha Köstlin-Gille","doi":"10.1002/eji.70056","DOIUrl":"10.1002/eji.70056","url":null,"abstract":"<p>Pregnancy requires immune tolerance to a semi-allogeneic fetus, involving profound adaptations, particularly in the T helper (Th) cell response. The intestinal microbiome plays a crucial role in health, but its influence on immune adaptation to pregnancy remains unclear. Bacterial extracellular vesicles (BEVs), released by gut bacteria, can cross the intestinal barrier and modulate immune responses. In our study we investigated the effect of fecal EVs (fEVs) from pregnant women on Th cell composition <i>in vitro</i>. fEVs were purified from preserved stool samples, characterized, and their uptake by immune cells was analyzed. Using an <i>in vitro</i> T cell culture model, we examined Th cell phenotypes, intracellular cytokine expression, and proteomic changes after stimulation with fEVs from pregnant and non-pregnant women. We demonstrate that fEVs from preserved stool samples are rapidly taken up by T cells and modulate their phenotype. Stimulation with fEVs from pregnant women shifts Th cells toward a regulatory profile favorable for pregnancy, increasing Th2 cells while reducing Th17 cells compared to fEVs from non-pregnant controls. This study provides the first <i>in vitro</i> evidence that fecal-derived EVs influence immune adaptation to pregnancy and may offer a basis for microbiome-targeted strategies to prevent or treat immunological pregnancy complications.</p>","PeriodicalId":165,"journal":{"name":"European Journal of Immunology","volume":"55 9","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/eji.70056","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145084625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tonia Bargmann, Sebastian Konzok, Renato Liguori, Maximilian Fuchs, Charline Sommer, Dirk Schaudien, Charlotte Schob, Stephan Halle, Christopher Werlein, Patrick Zardo, Lavinia Neubert, Danny Jonigk, Hans-Gerd Fieguth, Fulvia Ferrazzi, Katherina Sewald, Susann Dehmel, Armin Braun
Despite advancements in immunotherapies, the diversity of the tumor microenvironment remains a challenge for cancer treatment. To elucidate microenvironment-specific differences in antitumor responses, we established patient-derived ex vivo tumor-lung slices. We analyzed immune activation profiles after treatment with anti-CD3/CD28 and the checkpoint inhibitor Nivolumab. Lung slices from non-tumor, tumor-adjacent, tumor-border, and tumor-central tissue were generated and assessed for viability, cell composition, and immune competence via flow cytometry, soluble factor secretion, and bulk RNA-sequencing. The tumor-border contained the highest number of immune cells (8.3-fold vs. non-tumor), secreted tumor markers (S100 and CA15-3), and exhibited high levels of inflammatory mediators (IFNγ, IL-6, and IL-2). Treatment with anti-CD3/CD28 increased the frequency of CD137+/CD8+ T cells and induced cytokine responses dominated by IFNγ, IL-2, and Granzyme B. While both non-tumor and tumor-border tissue responded to anti-CD3/CD28, the intensities of immune responses were highly varied. Notably, treatment with Nivolumab induced an inflammatory response primarily in the tumor-border evidenced by IFNγ, IL-2, and Perforin secretion alongside increased expression of CD107a on CD8+ T cells, in a donor-dependent manner. Taken together, these data demonstrate how tumor-border tissue slices can be utilized to study T cell responses in the context of the patient-specific tumor microenvironment.
{"title":"Activation of CD8⁺ T Cells in the Human Ex Vivo Lung Tumor Microenvironment Using Anti-CD3/CD28 and Nivolumab","authors":"Tonia Bargmann, Sebastian Konzok, Renato Liguori, Maximilian Fuchs, Charline Sommer, Dirk Schaudien, Charlotte Schob, Stephan Halle, Christopher Werlein, Patrick Zardo, Lavinia Neubert, Danny Jonigk, Hans-Gerd Fieguth, Fulvia Ferrazzi, Katherina Sewald, Susann Dehmel, Armin Braun","doi":"10.1002/eji.70060","DOIUrl":"https://doi.org/10.1002/eji.70060","url":null,"abstract":"<p>Despite advancements in immunotherapies, the diversity of the tumor microenvironment remains a challenge for cancer treatment. To elucidate microenvironment-specific differences in antitumor responses, we established patient-derived <i>ex vivo</i> tumor-lung slices. We analyzed immune activation profiles after treatment with anti-CD3/CD28 and the checkpoint inhibitor Nivolumab. Lung slices from non-tumor, tumor-adjacent, tumor-border, and tumor-central tissue were generated and assessed for viability, cell composition, and immune competence via flow cytometry, soluble factor secretion, and bulk RNA-sequencing. The tumor-border contained the highest number of immune cells (8.3-fold vs. non-tumor), secreted tumor markers (S100 and CA15-3), and exhibited high levels of inflammatory mediators (IFNγ, IL-6, and IL-2). Treatment with anti-CD3/CD28 increased the frequency of CD137<sup>+</sup>/CD8<sup>+</sup> T cells and induced cytokine responses dominated by IFNγ, IL-2, and Granzyme B. While both non-tumor and tumor-border tissue responded to anti-CD3/CD28, the intensities of immune responses were highly varied. Notably, treatment with Nivolumab induced an inflammatory response primarily in the tumor-border evidenced by IFNγ, IL-2, and Perforin secretion alongside increased expression of CD107a on CD8<sup>+</sup> T cells, in a donor-dependent manner. Taken together, these data demonstrate how tumor-border tissue slices can be utilized to study T cell responses in the context of the patient-specific tumor microenvironment.</p>","PeriodicalId":165,"journal":{"name":"European Journal of Immunology","volume":"55 9","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/eji.70060","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145058005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Antonia Geisse, Tao Zhang, Jonathan Schreiber, Kristina Markova, Sophie Burkhalter, Hedda Wardemann, Andrew J. Macpherson, Tim Rollenske
Immunoglobulin (Ig) A is the main antibody isotype found on mucosal surfaces in mammals, where it is predominantly present as a dimer. Here we provide an easy, scalable, efficient, and broadly applicable method to produce and purify monoclonal mouse dimeric IgA from single B cell Ig transcripts to study mucosal antibody responses at single-cell level.